Thank you to our speakers, sponsors, and delegates who joined us in Boston for the 5th Glioblastoma Drug Development Summit! If you are interested in the 2025 event, please get in touch at info@hansonwade.com
Revolutionize GBM Treatment by Advancing the Development & Delivery of Effective Therapeutics
The huge unmet need for glioblastoma therapies reinforced the critical importance for the community to unite at the 5th Glioblastoma Drug Development Summit in Boston, March 2024 where we collaboratively addressed the recurring barriers to treatment success.
With promising clinical readouts from a range of therapeutic modalities, novel drug targets emerging and positive advances in state-of-the-art technologies like sonodynamic therapy, there was more promise within the GBM space than ever before.
Returning as the only industry-led, therapeutic agnostic event which brings together large pharma, biotech, neurosurgeons and world-renowned academics alongside investors with a shared mission: revolutionizing glioblastoma and CNS tumour drug development.
2024s pioneering line up included Mimivax, Polaris, Day One Biopharmaceuticals, Novartis, Bristol-Myers Squibb, and 25+ more.
The future of glioblastoma treatment starts here.
The 2024 World-Class Speaker Faculty Included:
Previous Attendees Include:
2024 Partner:
What past attendees had to say:
“Really good mix of content and participants - companies, researchers, clinicians, and investors. Appealing format, with great opportunities for interaction and networking”
James Garner, Chief Executive Officer, Kazia Therapeutics
“This is the most useful meeting of the year for learning the latest trials for glioblastomas and future directions”
Patrick Wen, Director, Center For Neuro-Oncology, Dana-Farber Cancer Institute
“Excellent content, highly qualified speakers, and network was made convenient and accessible”
Mike Choukas, Co-founder and Chief Executive Officer, Autem Therapeutics
“This was a highly well-organized, engaging and unique for this type of conference as it was science driven with excellent speakers and panel members”
Senior Director, Inovio Pharmaceuticals
“GBM DDS is the definitive meeting on GBM and an excellent opportunity to understand the length and breadth of drug development activity in this disease”
Chief Executive Officer, Kazia Therapeutics